StockData

Concord Medical Services vs Starling Oncology

CCM and STLN side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CCM and STLN compare

Starling Oncology grew revenue faster over the last twelve months (38.4% versus 19.9% for Concord Medical Services).

Starling Oncology keeps more of each dollar of sales as profit, with a net margin of −6.2% compared with −20.2% at Concord Medical Services.

Starling Oncology scores higher on the StockData Score (6 against 3 for Concord Medical Services), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCCMSTLN
Size and price
Market cap–$666M
Share price$3.57$6.53
Change, 1 year−32.6%38.9%
Change, 5 years−85.9%−34.6%
Beta (5Y)0.311.60
Employees610641
StockData Score
Total score36 (better)
Valuation score01 (better)
Growth score22
Performance score12 (better)
Health score01 (better)
Dividend score00
Valuation
P/S–1.1×
FCF yield–−0.49%
Growth
Revenue growth (TTM)19.9%38.4% (better)
Revenue growth, 5Y average15.6%21.8% (better)
Profitability
Gross margin5.6%–
Operating margin−56.8%−4.4% (better)
Net margin−20.2%−6.2% (better)
FCF margin−56.1%−0.56% (better)
Return on invested capital−19.3% (better)−83.1%
Financial health
Interest coverage−1.7× (better)−3.4×
Current ratio0.481.36 (better)
Altman Z-score–2.78
Piotroski F-score6 (better)3
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions0.03%43.4%
Held by insiders0.83%56.6%
Insider net buying, 12 months–−$122K

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.